Management
In a randomized controlled trial [PMID:19032727], dexibuprofen at doses of 5 mg/kg and 7 mg/kg demonstrated no statistically significant difference in fever reduction compared to 10 mg/kg ibuprofen.
The study [PMID:19032727] suggests that dexibuprofen at 5 mg/kg and 7 mg/kg is sufficient to control fever caused by upper respiratory tract infections in children, comparable to 10 mg/kg ibuprofen.
In a double-blind study [PMID:23659181], dexibuprofen at doses of 2.5-5 mg/kg (DEX 1) and 3.5-7 mg/kg (DEX 2) resulted in significantly less temperature elevation compared to ibuprofen (5-10 mg/kg) after 4 hours, particularly for those with initial temperatures ≥38.5°C.
The study [PMID:23659181] found no significant difference in temperature reduction between the lower dose dexibuprofen group (DEX 1) and the control group (ibuprofen) for children with initial temperatures below 38.5°C, indicating its efficacy in this subgroup.
The research [PMID:23659181] showed no significant differences in temperature reduction between the higher dose dexibuprofen group (DEX 2) and the ibuprofen control group across different initial temperature thresholds, suggesting similar efficacy.
Local delivery of antibiotics, such as fusafungine, enables higher drug concentrations at the infection site with smaller doses, leading to decreased systemic toxicity and fewer side effects [PMID:15537477].
Fusafungine, a naturally occurring peptide antibiotic, provides rapid symptomatic relief when administered locally to the respiratory mucosa [PMID:15537477].
Complications
No significant differences in adverse drug reactions were observed between dexibuprofen and ibuprofen groups in the clinical trial [PMID:19032727].
Key Recommendations
Given the viral origin and self-limiting nature of most upper respiratory tract infections, reducing the use of systemic antibiotics is crucial to mitigate antibiotic resistance [PMID:15537477]. (Evidence: Strong)
References
1 Yoon JS, Jeong DC, Oh JW, Lee KY, Lee HS, Koh YY et al.. The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection. British journal of clinical pharmacology 2008. link 2 Kim CK, Callaway Z, Choung JT, Yu JH, Shim KS, Kwon EM et al.. Dexibuprofen for fever in children with upper respiratory tract infection. Pediatrics international : official journal of the Japan Pediatric Society 2013. link 3 German-Fattal M, Mösges R. How to improve current therapeutic standards in upper respiratory infections: value of fusafungine. Current medical research and opinion 2004. link